Table 1 Baseline characteristics of patients and clinical response to the docetaxel plus carboplatin regimen.
Patient and disease feature from the diagnostic core | N = 9 (%) |
|---|---|
Age (year) | |
˂50 | 4 (45%) |
≥ 50 | 5 (55%) |
Menopausal status | |
Pre | 4 (45%) |
Post | 5 (55%) |
Clinical T-stage | |
T1 | 1 (11%) |
T2 | 5 (55%) |
T3 | 2 (23%) |
T4 | 1 (11%) |
Clinical N-stage | |
N0 | 2 (23%) |
N1 | 6 (66%) |
N2 | 1 (11%) |
N3 | 0 (0%) |
Symmans class | |
pCR | 3 (33%) |
RCB-I | 1 (11%) |
RCB-II | 3 (33%) |
RCB-III | 2 (23%) |
Clinical response (MRI) | |
Complete response | 2 (23%) |
Minor response | 5 (55%) |
Partial response | 1 (11%) |
Progression disease | 0 (0%) |
Stable disease | 1 (11%) |
Ki 67 expression | |
˂50 | 1 (11) |
≥ 50 | 8 (89%) |
Histologic grade | |
G1 | 0 (0%) |
G2 | 2 (23%) |
G3 | 6 (64%) |
No data | 1 (11%) |
Germline homologous recombination mutation | |
BRCA wt | 6 (66%) |
BRCA mut | 2 (22%) |
PALB2 mut | 1 (11%) |
Current status (the last follow-up date) | |
Recurrence and death | 2 (22%) |
Recurrence and alive | 1 (11%) |
Alive and no recurrence | 6 (66%) |
